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BRIEF DEFINITIVE REPORT
           Neuromyelitis optica (NMO) is currently the 
best-defi  ned acquired infl  ammatory demyelin-
ating disorder of the central nervous system 
(CNS) (  1, 2  ). NMO attacks optic nerves and 
spinal cord selectively and repeatedly. The 
preferential distribution and severity of lesions 
in NMO is poorly understood. Clinical, histo-
pathological, and immunobiological observa-
tions support a pathogenic role for an IgG 
autoantibody specifi  c for the astrocytic water 
channel aquaporin-4 (AQP4), and the severity 
of acute NMO is ameliorated by antibody-
depleting therapies (  1  ). In contrast to most 
infl  ammatory CNS demyelinating disorders, 
tissue destruction in NMO is profound. In 
addition to white matter lesions, NMO char-
acteristically exhibits central necrosis of spinal 
cord gray matter (  3  ). Histopathological CNS 
lesions lack AQP4 (  4  ) and show deposition of 
IgM and IgG and products of complement ac-
tivation in a vasculocentric pattern that coincides 
with the normal distribution of AQP4 (  4, 5  ). 
Until recently, NMO was considered a rare 
and severe variant of multiple sclerosis (MS). 
However, the advent of serological testing for 
AQP4-IgG has revealed that NMO and its in-
augural forms are more common than previously 
recognized. They tend to be misdiagnosed as 
MS, which lacks a specifi  c biomarker (  1  ). 
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  Neuromyelitis optica (NMO)-immunoglobulin G (IgG) is a clinically validated serum bio-
marker that distinguishes relapsing central nervous system (CNS) infl  ammatory demyelinat-
ing disorders related to NMO from multiple sclerosis. This autoantibody targets astrocytic 
aquaporin-4 (AQP4) water channels. Clinical, radiological, and immunopathological data 
suggest that NMO-IgG might be pathogenic. Characteristic CNS lesions exhibit selective 
depletion of AQP4, with and without associated myelin loss; focal vasculocentric deposits 
of IgG, IgM, and complement; prominent edema; and infl  ammation. The effect of NMO-IgG 
on astrocytes has not been studied. In this study, we demonstrate that exposure to NMO 
patient serum and active complement compromises the membrane integrity of CNS-derived 
astrocytes. Without complement, astrocytic membranes remain intact, but AQP4 is endocy-
tosed with concomitant loss of Na  +  -dependent glutamate transport and loss of the excit-
atory amino acid transporter 2 (EAAT2) . Our data suggest that EAAT2 and AQP4 exist in 
astrocytic membranes as a macromolecular complex. Transport-competent EAAT2 protein is 
up-regulated in differentiating astrocyte progenitors and in nonneural cells expressing 
AQP4 transgenically. Marked reduction of EAAT2 in AQP4-defi  cient regions of NMO pa-
tient spinal cord lesions supports our immunocytochemical and immunoprecipitation data. 
Thus, binding of NMO-IgG to astrocytic AQP4 initiates several potentially neuropathogenic 
mechanisms: complement activation, AQP4 and EAAT2 down-regulation, and disruption of 
glutamate homeostasis. 
© 2008 Hinson et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).2474 SEQUELAE OF NMO-IGG-ASTROCYTIC AQP4 INTERACTIONS   | Hinson et al. 
of complement, NMO-IgG causes antigen-specifi  c removal of 
AQP4 from astrocytic membranes with reduction of Na  +  -de-
pendent glutamate transport and loss of surface EAAT2; (c) 
transgenic expression of AQP4 in nonastrocytic cells, and 
physiological up-regulation of AQP4 in diff  erentiating astro-
cytes, induces surface EAAT2 expression; (d) AQP4 and 
EAAT2 exist in astrocytic membranes as a macromolecular 
complex; and (e) regions of AQP4 loss in NMO spinal cord 
lesions are defi  cient in EAAT2. 
    RESULTS AND DISCUSSION   
  NMO-IgG binding to primary astrocytes induces AQP4 
modulation and complement activation 
  We monitored AQP4 distribution after applying NMO 
or control serum to cerebral astrocytes. Serum containing 
NMO-IgG, but not control serum, induced rapid down-
regulation of surface AQP4 (  Fig. 1 A  ).   AQP4 coalesced 
in cytoplasmic vesicles reminiscent of those observed in 
GFP-AQP4  –  transfected nonneural cells exposed to NMO-
IgG (  6  ). 
  We evaluated the complement-activating capacity of 
NMO-IgG binding to astrocytic AQP4 by including com-
plement with NMO or control serum, and processing the 
cells for fl  ow cytometric analysis of propidium iodide infl  ux. 
In the presence of NMO-IgG and active complement, plasma 
membrane permeability increased by approximately twofold 
(P   <   0.007;   Fig. 1 B  ). With heat-inactivated complement, we 
observed no discernible eff  ect with control serum or NMO 
serum (  Fig. 1 B  ). Activation of early complement compo-
nents by IgG binding to the extracellular domain of AQP4 
  We recently demonstrated in vitro the pathogenicity of 
NMO-IgG for nonneural cells transgenically expressing 
AQP4, and that NMO serum IgM is not AQP4 specifi  c. 
Binding of NMO-IgG to the extracellular domain of AQP4 
reversibly down-regulates its plasma membrane expression 
(  6  ). In the presence of active complement, binding of NMO-
IgG to surface AQP4 initiated robust complement activation 
and rapid loss of the target cell membrane  ’  s integrity. We 
concluded that the abundant IgM deposits in CNS lesions of 
NMO patients are plasma-derived and enter through the 
breached blood  –  brain barrier after initial focal activation of 
complement by AQP4-IgG (  6  ). Multisystem autoimmune 
diseases frequently accompany NMO (  7  ), and the elevated 
circulating IgM that is characteristic of multisystem autoim-
munity has rheumatoid factor  –  like properties that could am-
plify the CNS infl  ammatory response in NMO (  6  ). 
  A recent report that astrocytes lacking AQP4 express a 
reduced level of the astrocytic Na  +  -dependent excitatory 
amino acid transporter 2 (EAAT2; homologue of rodent 
GLT-1 [  8  ]) led us to hypothesize that if NMO-IgG altered 
the expression of EAAT2 in astrocyte membranes, this might 
impair glutamate homeostasis (  6  ). Resulting overstimulation 
of glutamate receptors in neurons and oligodendrocytes could 
contribute indirectly to the pathobiology of NMO. EAAT2 
accounts for   >  90% of glutamate uptake in the CNS (  9  ), is 
critical for clearing glutamate from excitatory synapses, and is 
expressed selectively in astrocytes. 
  In this study, we demonstrate that: (a) when active com-
plement is present, binding of NMO-IgG to AQP4 in astro-
cyte membranes causes membrane lesioning; (b) in the absence 
    Figure 1.         In primary astrocytes, NMO-IgG induces internalization of AQP4, impairment of glutamate uptake, or complement activation.  
(A) Plasma membrane AQP4 (green) and cytoplasmic GFAP (red) after exposure to no human serum, control patient serum, or NMO patient serum. 
Serum containing NMO-IgG causes rapid translocation of surface AQP4 into cytoplasmic vesicles. Boxed area is enlarged in bottom images. Bars, 
10   μ  m. (B) Quantitation of membrane permeability after exposure to control or NMO serum. Increase in permeability to propidium iodide (PI) greater 
than twofold by NMO serum required active complement (     C    = inactivated complement). (C) Uptake of   L- [ 3 H]glutamate  ( ± Na + -containing  buffer) 
without human serum (white column) or in control (gray column) or NMO serum (crosshatched column). Excess unlabeled glutamate (black column) 
prevented   L- [ 3  H]glutamate uptake. NMO serum reduced   L- [ 3  H]glutamate uptake by 50%. The experiment shown in C was performed twice. All other 
experiments were done at least three times. The error bars represent the standard error of six and four replicates, respectively.   JEM VOL. 205, October 27, 2008  2475 
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that compromise of EAAT2 function through IgG-induced 
loss of AQP4 in NMO lesions might increase the extracellular 
concentration of glutamate in AQP4-rich regions critical to 
oligodendroglial and neuronal viability at nodes of Ranvier 
and perisynaptic regions (  6  ). 
  First, we compared Na  +  -dependent glutamate transport 
in astrocytes exposed to NMO or control sera (  Fig. 1 C  ). 
Uptake of   l-  [  3  H]glutamate was minimal (  <  200 counts/minute) 
in the absence of Na  +   or when excess unlabeled glutamate 
was present. In the presence of Na  +  ,   l-  [  3  H]glutamate uptake 
was increased to approximately 3,000 counts/min in cells un-
exposed to serum or exposed to control patient serum (  Fig. 1 C  ). 
These results are consistent with the uptake of  l- [  3  H]glutamate 
being Na  +   dependent and glutamate specifi  c. When serum 
containing NMO-IgG was added in these experimental 
conditions,   l-  [  3  H]glutamate uptake was reduced by     50% 
(P   <   0.0003;   Fig. 1 C  ). 
  NMO-IgG down-regulates both EAAT2 and AQP4 
from the surface of differentiated type 2 astrocytic cells 
  Attenuation of astrocytic   l-  [  3  H]glutamate uptake after expo-
sure to NMO-IgG parallels the loss of AQP4 protein. To in-
vestigate the possibility that EAAT2 protein may be lost 
secondary to loss of surface AQP4, we used EAAT2-specifi  c 
IgG to follow the fate of EAAT2 after exposing astrocytes to 
NMO-IgG. As noted by Stanimirovic et al. (  16  ), we con-
fi  rmed that EAAT1 and EAAT2 glutamate transporter levels 
in primary rat astrocyte membranes are too low to detect 
in astrocytes would increase CNS microvascular endothelial 
permeability and promote infl  ammatory cell infi  ltration. As-
sembly of the fi  nal membrane attack complex might focally 
damage endfeet, where AQP4 is expressed most highly (  6  ). 
However, a rich endowment of astrocytic membranes with 
complement regulatory proteins (  10  ) may explain their rela-
tive resistance to AQP4-IgG  –  dependent lysis in this study, in 
comparison to AQP4-transfected human embryonic kidney 
(HEK)-293 cells (  6  ). 
  NMO-IgG attenuates Na  +  -dependent glutamate uptake 
in astrocytes 
  Glutamate toxicity is commonly postulated as a downstream 
mechanism mediating progression of neurodegenerative pro-
cesses (for review see [  11  ]). The CNS extracellular concentra-
tion of glutamate is elevated in many neurodegenerative 
diseases. Its excitotoxic eff  ects on neurons are widely recog-
nized. However, oligodendrocytes are highly sensitive to exci-
totoxic signals mediated by calcium-permeable glutamate 
receptors (AMPA and kainate types; for review see [  12  ]) 
(  13-15  ). It is plausible that glutamate toxicity may contribute 
to demyelination through an eff  ect on oligodendroglia. These 
cells make and maintain the myelin sheaths that insulate CNS 
axons and are centrally involved in CNS infl  ammatory demy-
elinating disorders. A report that EAAT2 expression (Western 
blot and RT-PCR) is reduced in AQP4-null astrocytes (  8  ) 
prompted us to evaluate glutamate toxicity as a potential out-
come of IgG-induced AQP4 modulation. We hypothesized 
    Figure 2.         CG-4 glial cells in astrocytic differentiation medium up-regulate both AQP4 and EAAT2 expression; NMO serum down-regulates 
both.   (A) CG-4 cells cultured in proliferation medium (CG4-PM) do not express cytoplasmic GFAP (red). After 7 d in astrocytic differentiation medium 
(CG4-AM), a subset of cells contains brilliant cytoplasmic GFAP. (B) The Western blot shows that undifferentiated CG4-PM (PM) cell lysates contain mini-
mal EAAT2 or AQP4; both proteins are up-regulated in CG4-AM (AM). Markers indicate kilodalton reference standards. (C) AQP4 (green) and EAAT2 (red) 
are negligible in CG4-PM cells, but are up-regulated on the surface of CG4-AM cells; NMO serum, but not control patient serum, depletes both. DNA is 
blue (A and C). All experiments were performed a minimum of two times. Bars, 5   μ  m.     2476 SEQUELAE OF NMO-IGG-ASTROCYTIC AQP4 INTERACTIONS   | Hinson et al. 
plasma membrane of astrocytes is determined by dependence 
on astrocytic AQP expression. 
  We confi  rmed that upregulated EAAT2 protein in GFP-
AQP4 transfected cells was functional by demonstrating that 
GFP-AQP4 cells imported two- to threefold more glutamate 
via the Na  +  -dependent pathway relative to GFP vector cells 
(P   <   0.0002;   Fig. 3 F  ). It is noteworthy that glutamate trans-
port in Na  +  -containing buff  er was unchanged in GFP vector 
cells compared to GFP-AQP4 (  Fig. 3 F  ). We anticipated that 
constitutively expressed EAAT1 in both cell lines would 
confer higher glutamate transport in GFP vector cells in Na  +  -
containing buff  er than in buff  er lacking Na  +  . However, 
uptake of glutamate was unaff  ected in the presence of Na  +  , 
suggesting that EAAT1 expressed constitutively in these cells 
is not functional. 
  Plasma membrane loss of EAAT2 after exposure to NMO 
serum is EAAT2-selective and is dependent on the presence 
of both AQP4 protein and NMO-IgG 
  Our data indicate that the concentration of AQP4 protein 
in the plasma membrane and Na  +  -dependent glutamate 
transport are both reduced by exposure of primary astro-
cytes to NMO-IgG (  Fig. 1  ). Our observations in diff  eren-
tiated CG-4 type 2 astrocytes suggest that the effect on 
glutamate transport in primary astrocytes is caused by 
plasma membrane loss of EAAT2 (  Fig. 2  ). To further in-
vestigate the association between AQP4 and EAAT2, we 
evaluated the eff  ect of NMO and control sera on both 
EAAT1 and EAAT2. Control serum did not appreciably 
aff  ect localization or expression of the EAAT2 transporter. 
However, serum containing NMO-IgG induced rapid sur-
face down-regulation of both GFP-AQP4 and EAAT2 
(  Fig. 4 A  ).   Higher magnifi  cation (  Fig. 4 A  ) revealed appar-
ent colocalization of EAAT2 and AQP4 in early endosomal 
vesicles to which we previously demonstrated AQP4 trans-
location after exposure to NMO serum (  6  ). We evaluated 
the localization of AQP4 and the early endosome antigen-
1 marker after exposing the cells to NMO serum for 10 min. 
The white color that resulted when the images were merged 
suggested partial colocalization of AQP4 and EAAT2 in 
early endosomes (  Fig. 4 B  ). However, separate vesicles in 
close proximity or overlapping in the z axis would yield the 
same result. 
  We excluded the possibility that NMO serum might 
contain EAAT2-specifi  c IgG in addition to AQP4 IgG, by 
testing the eff  ect of NMO serum on plasma membrane ex-
pression of EAAT2 in HEK-293 cells transfected with AQP5-
GFP ( Fig. 4 C ). Those cells express both EAAT1 and EAAT2, 
but are devoid of AQP4 (  Fig. 3  ). Exposure to NMO-IgG did 
not aff  ect the distribution of EAAT1 or EAAT2 in AQP5-
GFP cells (  Fig. 4, C and E  ). 
  To investigate the specifi  city of EAAT2 down-regula-
tion, we evaluated the eff  ect of NMO-IgG on the EAAT1 
glutamate transporter, which is expressed constitutively in 
nonneural HEK-293 cells (  Fig. 3 E  ). NMO patient sera did not 
appreciably aff  ect EAAT1 expression in these cells (  Fig. 4 D  ), 
by immunofl  uorescence staining. We therefore investigated 
EAAT2 expression in the bipotential glial cell line CG-4, 
which is derived from O2-A progenitor cells in the develop-
ing rat CNS. In prescribed culture conditions (  17  ), CG-4 
cells diff  erentiate into type 2 astrocytes. In proliferation-pro-
moting medium (containing bFGF and PDGF), the cells 
(CG4-PM) lack GFAP intermediate fi  laments  (  Fig. 2 A  ).   
However, in medium with growth factors replaced by a high 
concentration of fetal bovine serum, type 2 astrocyte diff  er-
entiation is evident in the cells (CG4-AM) by morphology 
and GFAP immunoreactivity (  Fig. 2 A  ). In cells grown for 
7 d in astrocyte diff  erentiation medium, plasma membrane 
expression of both AQP4 and EAAT2 is enhanced (  Fig. 2, B 
and C  ). However, when NMO serum is added to CG4-AM 
cells at day 7, both AQP4 and EAAT2 are depleted from the 
plasma membrane (  Fig. 2 C  ). Addition of control sera in 
identical conditions does not discernibly aff  ect expression of 
either AQP4 or EAAT2 (  Fig. 2 C  ). Concomitant loss of both 
EAAT2 and AQP4 plausibly explains the reduced glutamate 
transport that we observed in cultured astrocytes exposed to 
NMO-IgG. 
  EAAT2 expression is up-regulated when AQP4 protein 
expression is induced in nonneural cells 
  AQP4 and EAAT2 are both enriched in the astrocytic endfoot 
membrane (  18  ). Our fi  nding that both are depleted from 
plasma membranes of cultured astrocytes exposed to NMO-
IgG is consistent with the notion that EAAT2 expression de-
pends on AQP4 expression. To further evaluate the relationship 
between AQP4 and glutamate transport, we studied the HEK-
293 nonneural cell line, comparing EAAT2 expression in cells 
stably expressing GFP, GFP-AQP4, or a nonneural AQP, 
AQP5-GFP ( Fig. 3 ).   We readily detected EAAT1 in the plasma 
membranes of cell lines transfected with either GFP vector or 
GFP-AQP4 (  Fig. 3 A  ). We did not detect EAAT2 in GFP 
vector-transfected cells (  Fig. 3 B  ), but EAAT2 was strikingly 
upregulated in the plasma membrane of cells transgenically ex-
pressing either AQP4 or AQP5 (  Fig. 3 B  ). 
  To determine whether this observed increase in mem-
brane EAAT2 and functional glutamate transport might re-
fl  ect an increase in EAAT2 gene transcription or protein 
expression, we examined EAAT2 transcripts by RT-PCR. 
The three transfected HEK-293 lines expressed EAAT2 tran-
scripts at similar levels (  Fig. 3 C  ). Western blot analyses (  Fig. 
3 D  ) supported our immunofl  uorescence observations that 
transgenic EAAT2 protein expression is upregulated when 
AQP4 or AQP5 is expressed in HEK-293 cells by compari-
son with cells transfected with vector alone. Expression of 
EAAT2 protein on the surface of cells expressing AQP might 
be increased through upregulated mRNA translation or, al-
ternatively, through a posttranslational modifi  cation increas-
ing EAAT2 protein stability or traffi   cking to the plasma 
membrane. These complementary observations accord with 
reports that EAAT2 protein expression is restricted to astro-
cytes, despite ubiquitous expression of EAAT2 mRNA (  11  ). 
We conclude that restriction of EAAT2 expression to the JEM VOL. 205, October 27, 2008  2477 
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tamate transport accompanying AQP4 down-regulation af-
ter exposure to NMO-IgG further supports our suggestion 
that AQP4 and EAAT2 are associated functionally in the 
plasma membrane. 
  AQP4 and EAAT2 coimmunoprecipitate 
  EAAT2 and EAAT1 are enriched in separate microdomains of 
the astrocytic plasma membrane (  18, 19  ); EAAT2 is enriched 
in contrast to EAAT2 loss from the plasma membrane. 
These results imply a specifi  c association between AQP4 
and EAAT2 that does not exist for EAAT1. The rapid 
down-regulation of EAAT2 and AQP4 induced by NMO-
IgG in GFP-AQP4-expressing cells and colocalization of 
both proteins in cytoplasmic endocytotic vesicles within 10 
min is consistent with a direct eff  ect of IgG on a surface 
macromolecular complex. The reduction in astrocytic glu-
    Figure 3.         Expression of AQP proteins in HEK-293 cells induces EAAT2 protein expression.   DNA is stained blue (A and B). (A) EAAT1 (red) is ex-
pressed constitutively, regardless of transfection. (B) EAAT2 (red) is localized in the plasma membrane of cells expressing AQP4 or AQP5 (green), but is 
undetectable in cells transfected with GFP-vector lacking an AQP cDNA. Bars, 10   μ  m. (C) For RT-PCR, all three cell lines express EAAT2 mRNA, regardless 
of AQP expression. Markers indicate basepair reference standards. (D) The Western blot shows that EAAT2 protein is up-regulated in cells transfected with 
AQP4 or AQP5, but not in GFP-vector  –  transfected cells. (E) EAAT1 protein and actin are expressed constitutively. Markers indicate kilodalton reference 
standards (D and E). (F) In glutamate transport experiments, GFP-AQP4 cells take up approximately threefold more   L- [ 3  H]glutamate than vector-trans-
fected cells (note: Na  +   dependence). All experiments were performed a minimum of two times. The error bars represent the standard error of six and four 
replicates,  respectively.     2478 SEQUELAE OF NMO-IGG-ASTROCYTIC AQP4 INTERACTIONS   | Hinson et al. 
  Colocalization of AQP4 and EAAT2 in CNS tissue 
  Our observations in primary astrocytes, type 2 diff  erenti-
ated CG-4 cells, and transfected nonneural HEK-293 cells 
indicate that the interaction of NMO-IgG with AQP4 in-
duces at least three possible outcomes, each potentially 
pathogenic: (a) complement activation, (b) down-regula-
tion of AQP4, and (c) coupled down-regulation of the 
EAAT2 glutamate transporter. Our immunohistochemical 
analysis of nonpathologic human CNS tissue (both corti-
cal and spinal cord) reveal that EAAT2, but not EAAT1, 
normally colocalizes with AQP4 in gray matter astrocytes 
(  Fig. 5 A  ) and that EAAT2 is most enriched in spinal 
cord gray matter (  Fig. 5 B  , top).   These fi  ndings were re-
producible and consistent with published rodent cord 
fi  ndings (  19, 29  ). 
in regions that highly express AQP4 (  18  ). Our data suggest that 
EAAT2 and AQP4 exist as a macromolecular complex. When 
exposed to NMO-IgG, both are translocated from the plasma 
membrane to an endolysosomal-targeted population of cyto-
plasmic vesicles (  Fig. 4, A and B  ). To evaluate potential physi-
cal interaction, we solubilized GFP-AQP4  –  transfected cells 
and probed the lysates with EAAT2-IgG. Addition of protein 
G-agarose captured both EAAT2 and AQP4 (  Fig. 4 F  ). We 
obtained similar data using independent IgGs recognizing dif-
ferent EAAT2 epitopes (unpublished data). As a specifi  city 
control, we compared results obtained using EAAT1-IgG as a 
probe for the cell lysates. In contrast to EAAT2-IgG, EAAT1-
IgG did not pull down AQP4. These results support the exis-
tence of AQP4 and EAAT2 as a macromolecular complex 
independent of EAAT1. 
    Figure 4.         NMO-IgG modulation of AQP4 from transfected HEK-293 membranes down-regulates EAAT2 expression.  GFP-AQP4 –   or  AQP5-
GFP  –  transfected cells (green) were probed with anti-EAAT2 or   –  EAAT1-IgG (red) after exposure to control or NMO patient serum (37  °  C; 4 h). Nuclear DNA 
is blue. (A) NMO serum caused membrane loss of both AQP4 and EAAT2; control serum did not affect the distribution of either. Enlarged images show 
both EAAT2 and AQP4 internalized in cytoplasmic vesicles after exposure to NMO serum. (B) Staining with early endosome marker (EEA1, purple) after 
10-min exposure to NMO serum shows colocalization of both GFP-AQP4 and EAAT2 (arrows) in endocytotic vesicles (white spots in merged image). 
(A and B) Boxed areas are enlarged in the bottom image. (C) NMO serum does not selectively affect EAAT2 in cells transfected with AQP5. EAAT1 is not 
affected by NMO or control serum in cells transfected with AQP4 (D) or AQP5 (E). (F) Western blot shows NMO-IgG or IgG specifi  c for GFP, AQP4, or 
EAAT2, capture GFP-AQP4 protein; GFP-AQP4 does not coprecipitate with control patient IgG or EAAT1-specifi  c IgG. Markers indicate kilodalton reference 
standards. All experiments were performed a minimum of two times. Bars: (A, C, D, and E) 10   μ  m; or (B) 20   μ  m.     JEM VOL. 205, October 27, 2008  2479 
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NMO spinal cord tissue and contrasts with the increases in 
EAAT2 and AQP4 reported in both active and chronic MS 
lesions (  20  ). We conclude that diff  erences in regulation of 
glutamate homeostasis further distinguish NMO from classi-
cal MS (  1  ). 
  Concluding remarks 
  The data we present from studies of living astrocytes, pa-
tient and control sera, normal human spinal cord tissue, 
and spinal cord tissues from a patient with typical NMO, 
both non-lesioned and lesioned, provide the fi  rst evidence 
supporting a pathogenic role for NMO-IgG in disrupting 
glutamate transport. Because astrocytes are relatively toler-
ant of increased glutamate concentrations (  21  ), disruption 
of glutamate homeostasis by NMO-IgG has particular 
excitotoxic potential for neurons and oligodendrocytes. 
A focal increase of extracellular glutamate levels secondary 
to NMO-IgG  –  induced down-regulation of AQP4 may 
suffi   ce to injure or kill oligodendrocytes that express cal-
cium-permeable glutamate receptors (  15, 22  ). Oligoden-
drocytes in the spinal cord and optic nerve, which are 
principal sites of demyelination in NMO, are particularly 
sensitive to changes in glutamate concentration. Modest 
elevation of extracellular glutamate concentration renders 
oligodendrocytes additionally susceptible to Ig-indepen-
dent (alternative pathway) complement attack (  23  ). The 
potential pathogenic sequelae we demonstrate in this study 
for NMO-IgG binding to AQP4-rich membranes in pri-
mary astrocytes are both competing and cooperative. De-
pletion of AQP4 water channels in the plasma membrane 
would disrupt water homeostasis and promote edema. If 
complement were lacking, the consequences of impaired 
glutamate transport would be particularly deleterious for oli-
godendrocytes and neurons. 
  Outcomes of therapies directed at glutamate receptors 
have been unimpressive for neurodegenerative conditions 
where glutamate toxicity has been implicated in disease 
progression (for review see [  24  ]). However, our demonstra-
tion that the major astrocytic glutamate transporter EAAT2 
exists in a macromolecular complex with the AQP4 water 
channel, and is down-regulated by AQP4-specifi  c autoanti-
bodies that are restricted to patients with the NMO-spec-
trum of CNS infl   ammatory autoimmune demyelinating 
disorders, has unanticipated pathogenic implications for 
glutamate toxicity as a central mechanism in a spectrum of 
disorders that are commonly mistaken for MS. NMO is 
now recognized as a potentially reversible IgG-mediated at-
tack on astrocytic water channels (  1  ). The results we ob-
tained from studies of serum and spinal cord tissue of patients 
with NMO hold promise for novel therapeutic strategies 
for the management of NMO-spectrum disorders. For ex-
ample, it might be feasible to ameliorate tissue damage in 
both gray and white matter if therapeutic upregulation of 
EAAT2 can be achieved in patients whose neurological 
dysfunction is attributable to AQP4 autoimmunity. 
  NMO spinal cord lesions lack both AQP4 and EAAT2 
  Loss of AQP4 is a distinctive fi  nding in both early and late 
lesions of NMO (  4  ). NMO spinal cord tissue of normal ap-
pearance expresses normal levels of APQ4 and EAAT2 and 
lacks evidence of complement deposition (  Fig. 5 B  ). Le-
sioned NMO spinal cord gray matter contrasts to normal ap-
pearing gray matter by exhibiting markedly reduced EAAT2, 
in addition to AQP4 loss and deposition of complement ac-
tivation products (  Fig. 5 B  ). Together, these fi  ndings are 
consistent with absence of EAAT2 staining being a biologi-
cal phenomenon within the NMO lesion. AQP4 loss at sites 
of C9neo deposition is a representative fi  nding in our nine 
previously published cases (  4  ). EAAT2 loss may partially ac-
count for the destructive involvement of spinal cord gray 
matter which is characteristic of NMO. Lesions in MS CNS 
tissues are typically not necrotic. The marked loss of EAAT2 
described in this report parallels loss of AQP4 in lesioned 
    Figure 5.         Glutamate transporter expression in human tissue. 
  (A) Normal spinal cord from a single subject. Duplicate sections were dual 
stained for AQP4 (red) and EAAT2 or EAAT1 (green), i.e., four sections. 
Merged images show AQP4 and EAAT2 colocalization (top, yellow), but no 
colocalization of AQP4 and EAAT1 (bottom); mn, motor neuron. (B) Spinal 
cord tissue from a single NMO-IgG  –  seropositive patient. Three sections of 
nonlesioned lumbar region (top) serve as staining control for lesioned 
cord (bottom). The lack of complement deposition (C9neo, brick red in 
lesioned cord, bottom) and high expression of AQP4 in both white and 
gray matter are typical of normal cord tissue; EAAT2 is highly enriched in 
gray matter. Prominent deposition of C9neo in gray matter of lesioned 
thoracic cord (bottom, same patient) corresponds to focal regions of 
AQP4 and EAAT2 loss in adjacent sections. AQP4 is partially retained in 
the white matter. Asterisk, central canal. Bars: (A) 20   μ  m; (B) 200   μ  m.     2480 SEQUELAE OF NMO-IGG-ASTROCYTIC AQP4 INTERACTIONS   | Hinson et al. 
Na  +   (Krebs buff  er containing 120 mM NaCl, or 120 mM choline chloride, 
in 25 mM Tris, 5 mM KCl, 1 mM KH  2  PO  4  , 1 mM MgSO  4  , 2 mM CaCl  2  , 
and 555 mM   d-  glucose, pH 7.4). Both buff  ers contained 40   μ  M unlabeled 
glutamate. After 5 min at 37  °  C, we transferred the cells to 4  °  C, washed ex-
tensively with PBS, lysed in 0.1 M NaOH, and measured uptake of radiola-
beled glutamate using a Beckman Coulter LS 6000SC scintillation counter. 
For all experimental conditions, we performed quadruplicate assays and cal-
culated glutamate uptake as counts/minute/well, with and without Na  +  . 
  To assay glutamate uptake in GFP vector and GFP-AQP4 stable HEK-
293 cells, we used an alternative HEK-293  –  optimized protocol (  28  ). We 
defi  ned EAAT2-specifi  c transport as the diff  erence in glutamate uptake be-
tween GFP vector cells and GFP-AQP4  –  transfected cells. 
  Isolation of RNA and RT-PCR analysis.    We isolated total RNA from trizol-
lysed cells, and generated double-stranded cDNA using Superscript III First Strand 
Synthesis kit with random hexamer primers (according to Invitrogen protocols). 
To avoid amplifying contaminating genomic DNA, we used primer pairs that 
anneal in adjacent exons, as follows: AQP4 (forward, 5    -TGCACCAGGAA-
GATCAGCATCG-3    ; reverse, 5    -CAGGTCATCCGTCTCTACCTG-3    ) 
and EAAT2 (forward, 5    -GGTGGAAGTGCGAATGCACGACAGTCATC-
3    ; reverse, 5    -CCTCGTCTGGCGGTGGTGCAACCAGGAC-3    ). We am-
plifi  ed     -actin as a control. 
  Immunoprecipitation and Western blot.     Protocols were as previously 
described (  2  ). Commercial antibodies (AQP4, EAAT1, EAAT2, or GFP; 
2   μ  g/ml), or human sera (a high-titer pool of NMO patient or control pa-
tient sera; 30   μ  l/ml) were used as probes. Immune complexes released from 
protein G-agarose were resolved by electrophoresis (4  –  15% gradient poly-
acrylamide, room temperature). We exposed transblotted, blocked proteins 
for 1 h to IgG specifi  c for the following: GFP (1:1,000), AQP4 (1:500), 
EAAT1 (1:200), actin (1:2,000), or EAAT2 (1:200); we then probed the 
proteins with horseradish peroxidase  –  conjugated goat anti  –  mouse IgG 
or goat anti  –  rabbit IgG, and detected bound IgG autoradiographically 
(SuperSignal West Pico Chemiluminescence; Thermo Fisher Scientifi  c). 
  Statistical analysis.     We calculated signifi  cance using the Student  ’  s   t   test 
(two-tailed). 
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